Susquehanna International Group’s TherapeuticsMD TXMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-97,300
| Closed | -$544K | – | 13523 |
|
|
2022
Q4 | $544K | Sell |
97,300
-20,900
| -18% | -$123K | ﹤0.01% | 7629 |
|
|
2022
Q3 | $785K | Sell |
118,200
-30,100
| -20% | -$244K | ﹤0.01% | 7286 |
|
|
2022
Q2 | $1.48M | Buy |
148,300
+145,376
| +4,972% | +$1.39M | ﹤0.01% | 5573 |
|
|
2022
Q1 | $56K | Sell |
2,924
-1,898
| -39% | -$29.9K | ﹤0.01% | 12266 |
|
|
2021
Q4 | $87K | Sell |
4,822
-3,390
| -41% | -$102K | ﹤0.01% | 12232 |
|
|
2021
Q3 | $304K | Buy |
8,212
+196
| +2% | +$8.7K | ﹤0.01% | 10578 |
|
|
2021
Q2 | $477K | Sell |
8,016
-4,950
| -38% | -$300K | ﹤0.01% | 9715 |
|
|
2021
Q1 | $869K | Buy |
12,966
+9,054
| +231% | +$709K | ﹤0.01% | 8095 |
|
|
2020
Q4 | $237K | Buy |
3,912
+302
| +8% | +$20.6K | ﹤0.01% | 9755 |
|
|
2020
Q3 | $285K | Sell |
3,610
-4,818
| -57% | -$384K | ﹤0.01% | 8817 |
|
|
2020
Q2 | $527K | Buy |
8,428
+2,768
| +49% | +$161K | ﹤0.01% | 7256 |
|
|
2020
Q1 | $300K | Buy |
5,660
+1,232
| +28% | +$122K | ﹤0.01% | 7973 |
|
|
2019
Q4 | $536K | Buy |
4,428
+602
| +16% | +$86.6K | ﹤0.01% | 6855 |
|
|
2019
Q3 | $694K | Buy |
3,826
+1,190
| +45% | +$168K | ﹤0.01% | 6544 |
|
|
2019
Q2 | $343K | Sell |
2,636
-2,372
| -47% | -$425K | ﹤0.01% | 8059 |
|
|
2019
Q1 | $1.22M | Buy |
5,008
+2,254
| +82% | +$596K | ﹤0.01% | 4634 |
|
|
2018
Q4 | $525K | Sell |
2,754
-2,316
| -46% | -$565K | ﹤0.01% | 5950 |
|
|
2018
Q3 | $1.66M | Buy |
5,070
+908
| +22% | +$278K | ﹤0.01% | 4296 |
|
|
2018
Q2 | $1.3M | Sell |
4,162
-1,010
| -20% | -$309K | ﹤0.01% | 4813 |
|
|
2018
Q1 | $1.26M | Buy |
5,172
+3,510
| +211% | +$985K | ﹤0.01% | 4768 |
|
|
2017
Q4 | $502K | Sell |
1,662
-3,046
| -65% | -$848K | ﹤0.01% | 6628 |
|
|
2017
Q3 | $1.25M | Buy |
4,708
+1,380
| +41% | +$399K | ﹤0.01% | 4858 |
|
|
2017
Q2 | $877K | Sell |
3,328
-54
| -2% | -$13.5K | ﹤0.01% | 5538 |
|
|
2017
Q1 | $1.22M | Sell |
3,382
-3,890
| -53% | -$1.2M | ﹤0.01% | 4723 |
|
|
2016
Q4 | $2.1M | Buy |
+7,272
| New | +$2.25M | ﹤0.01% | 3961 |
|
|
2016
Q3 | – | Sell |
-1,114
| Closed | -$473K | – | 9072 |
|
|
2016
Q2 | $473K | Sell |
1,114
-1,306
| -54% | -$538K | ﹤0.01% | 6220 |
|
|
2016
Q1 | $774K | Sell |
2,420
-1,214
| -33% | -$414K | ﹤0.01% | 5595 |
|
|
2015
Q4 | $1.88M | Sell |
3,634
-180
| -5% | -$66.5K | ﹤0.01% | 4149 |
|
|
2015
Q3 | $1.12M | Buy |
3,814
+1,636
| +75% | +$582K | ﹤0.01% | 5501 |
|
|
2015
Q2 | $856K | Buy |
2,178
+1,166
| +115% | +$411K | ﹤0.01% | 6545 |
|
|
2015
Q1 | $306K | Buy |
1,012
+800
| +377% | +$195K | ﹤0.01% | 7947 |
|
|
2014
Q4 | $47K | Buy |
+212
| New | +$43.7K | ﹤0.01% | 9372 |
|
Other funds holding TXMD
RCMNY
CC
SCM
VCM
TC
ACM
Susquehanna International Group's TXMD Position: Q1 2026 in Review
Susquehanna International Group reduced its TherapeuticsMD (TXMD) stake by 40% in Q1 2026, selling an estimated $31.4K and leaving 21,220 shares worth $42.9K. The position accounts for ﹤0.01% of the portfolio, ranked #12674.
Susquehanna International Group first reported a position in TXMD in Q4 2013 and has held it in 36 quarters since. The position peaked at $8.45M in Q3 2018. 49 funds tracked by Wall St. Rank hold TXMD as of Q1 2026.
- Susquehanna International Group held 21,220 shares of TherapeuticsMD worth $42.9K as of Q1 2026.
- Susquehanna International Group sold 13,944 TherapeuticsMD shares in Q1 2026, an estimated $31.4K.
- TherapeuticsMD made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #12674 holding.
- Susquehanna International Group first reported a position in TherapeuticsMD in Q4 2013 and has held it in 36 quarters since.
- Susquehanna International Group's TherapeuticsMD position peaked at $8.45M in Q3 2018.
- 49 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2026.
Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.